Monoclonal antibodies are shown to be safe and effective in patients with dyslipidaemia

A new class of cholesterol drug, PCSK9 inhibitors, can reduce mortality and significantly reduce low density lipoprotein (LDL) cholesterol and lipoprotein in patients with hypercholesterolaemia, a meta-analysis published in the Annals of Internal Medicine has found.1